IQVIA Digital Site Suite

  1. How To Boost Support To Sites With Digital Clinical Technologies During The COVID-19 Crisis And Beyond 5/9/2020

    Digital solutions previously viewed as “nice to have” for clinical trial optimization are now proving to be vital to support sites. Here are five areas where we have seen sponsors take advantage of digital clinical technologies to boost support to sites and enable innovative drug development to continue - not only during the COVID-19 crisis but well into the future.

  2. Staying Connected In Crisis: Strong Site Communication Channels Stand Up To Pressure 4/14/2020

    The COVID-19 pandemic is presenting unprecedented challenges to the clinical trial industry. Sites are in an unprecedented state of flux, and the pressure to understand the situation, protect patients and providers, and determine how to ensure continuity is on. Now more than ever, strong communication channels between sponsors and sites are critical.

  3. Considerations When Implementing New Technology At Clinical Trial Sites 3/3/2020

    More than 10 years ago, the digital revolution came to the clinical trials industry, ushering in a host of new technologies for sites worldwide. While a few technologies were lauded, many sites found themselves overwhelmed by the sheer number of new offerings and frustrated by the numerous solutions proposed by sponsors that ultimately made trials more difficult. There are many steps that organizations can take to implement a site-first approach to ensure their tools aren’t missing the mark.

  4. Preventing Information Overload - Using Study Portals To Engage Site Staff 3/2/2020

    For many sites, the overabundance of communications through email, system notifications, or other means isn’t just common, it’s standard. To combat this, sponsors have been using study portals to employ a traditional mix of best practices and tailored communication styles. This approach works because it covers the core needs of all clinical trial sites while also addressing the two different types of site users.

  5. Alnylam Puts Sites And Patients First With IQVIA Technologies Investigator Site Portal

    When Alnylam Pharmaceuticals began developing medicines for rare diseases with few or no treatment options, the company’s leaders knew they needed to design clinical trials that kept patient well-being and disease burden at the forefront.